Objective:

To compare the efficacy and safety of DEB-BACE with cBACE in patients with lung cancer.

Approach:

• Search Strategy: A systematic search was conducted in PubMed, Embase, the Cochrane Library, and Web of Science for studies comparing DEB-BACE with cBACE.
• Inclusion Criteria: Included randomized controlled trials, prospective and retrospective cohort studies that compared DEB-BACE with cBACE, reporting on tumor response and treatment-related adverse events.

Key Findings:

• DEB-BACE was associated with higher pooled Objective Response Rate (ORR) at 1–3 months (OR = 5.38, 95% CI: 2.30–12.60) and 6 months (OR = 4.18, 95% CI: 1.90–9.19).
• DEB-BACE showed higher pooled Disease Control Rate (DCR) at 1–3 months (OR = 7.00, 95% CI: 1.99–24.60) and 6 months (OR = 5.40, 95% CI: 2.14–13.62).
• No significant differences were observed in adverse events such as hemoptysis, fever, chest discomfort, cough/sputum production, or nausea/vomiting.

Interpretation:

Current evidence suggests that DEB-BACE may provide better short-term tumor response compared to cBACE without a significant increase in adverse events.

Limitations:

• The evidence base is small and mainly observational, which may limit the generalizability of the findings.
• Comparator definitions were heterogeneous, potentially affecting the comparison outcomes.

Conclusion:

Findings warrant confirmation in well-designed multicenter randomized trials.